EP2069768A4 - Zusammensetzungen und verfahren zur diagnose und behandlung von typ-2-diabetes - Google Patents

Zusammensetzungen und verfahren zur diagnose und behandlung von typ-2-diabetes

Info

Publication number
EP2069768A4
EP2069768A4 EP07754400A EP07754400A EP2069768A4 EP 2069768 A4 EP2069768 A4 EP 2069768A4 EP 07754400 A EP07754400 A EP 07754400A EP 07754400 A EP07754400 A EP 07754400A EP 2069768 A4 EP2069768 A4 EP 2069768A4
Authority
EP
European Patent Office
Prior art keywords
diabetes
diagnosis
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07754400A
Other languages
English (en)
French (fr)
Other versions
EP2069768A2 (de
Inventor
Cohava Gelber
Liping Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Type Culture Collection ATCC
Original Assignee
American Type Culture Collection ATCC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Type Culture Collection ATCC filed Critical American Type Culture Collection ATCC
Publication of EP2069768A2 publication Critical patent/EP2069768A2/de
Publication of EP2069768A4 publication Critical patent/EP2069768A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
EP07754400A 2006-09-01 2007-03-28 Zusammensetzungen und verfahren zur diagnose und behandlung von typ-2-diabetes Withdrawn EP2069768A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84171706P 2006-09-01 2006-09-01
PCT/US2007/007875 WO2008030273A2 (en) 2006-09-01 2007-03-28 Compositions and methods for diagnosis and treatment of type 2 diabetes

Publications (2)

Publication Number Publication Date
EP2069768A2 EP2069768A2 (de) 2009-06-17
EP2069768A4 true EP2069768A4 (de) 2010-01-20

Family

ID=39157723

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07754400A Withdrawn EP2069768A4 (de) 2006-09-01 2007-03-28 Zusammensetzungen und verfahren zur diagnose und behandlung von typ-2-diabetes

Country Status (6)

Country Link
EP (1) EP2069768A4 (de)
JP (1) JP2010502946A (de)
CN (1) CN101563597A (de)
AU (1) AU2007293465A1 (de)
CA (1) CA2661332A1 (de)
WO (1) WO2008030273A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300170A1 (en) * 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
US20090203602A1 (en) 2006-09-01 2009-08-13 Cohava Gelber Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2010011860A1 (en) 2008-07-23 2010-01-28 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes
WO2010132447A2 (en) 2009-05-11 2010-11-18 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes using differential protein glycosylation
JP5812701B2 (ja) * 2010-06-23 2015-11-17 アークレイ株式会社 血漿グルコース測定方法
WO2012000058A1 (en) * 2010-07-02 2012-01-05 Newsouth Innovations Pty Limited Inheritance of metabolic dysfunction
SG10201806648TA (en) 2011-07-01 2018-09-27 Ngm Biopharmaceuticals Inc Compositions, uses and methods for treatment of metabolic disorders and diseases
US9963494B2 (en) 2012-11-28 2018-05-08 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN105008548B (zh) 2012-12-27 2020-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态以及治疗胆汁酸紊乱和疾病的方法
MX2016004822A (es) 2013-10-28 2016-08-17 Ngm Biopharmaceuticals Inc Modelos de cancer y metodos asociados.
LT3097122T (lt) 2014-01-24 2020-07-27 Ngm Biopharmaceuticals, Inc. Antikūnai, surišantys beta kloto domeną 2, ir jų panaudojimo būdai
CN103969234B (zh) * 2014-04-17 2017-02-15 山东东兴汇智生物科技有限公司 一种荧光素酶‑多抗原融合蛋白以及蛋白a琼脂糖‑融合蛋白‑抗体复合物
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
CA2951153A1 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
IL251834B2 (en) 2014-10-23 2023-09-01 Ngm Biopharmaceuticals Inc Pharmaceutical compositions containing peptide variants and methods of using them
WO2016073855A1 (en) * 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CN106906278A (zh) * 2015-12-22 2017-06-30 复旦大学 预测ii型糖尿病心血管并发症风险的生物标记物及其用途
AU2017315459B2 (en) 2016-08-26 2023-06-29 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN111758029B (zh) * 2018-02-27 2023-06-09 新加坡科技研究局 用于糖肽鉴定的方法、装置和计算机可读介质
CN108872293A (zh) * 2018-08-10 2018-11-23 厦门大学 一种肝泡型包虫病的代谢组学分析及初步筛查模型的构建方法
CN113539470A (zh) * 2020-04-14 2021-10-22 郑州大学第一附属医院 一种糖尿病肾病及非糖尿病性肾脏疾病鉴别诊断预测模型及构建方法
CN114404589B (zh) * 2021-12-24 2023-06-30 浙江大学 Rnase4作为治疗和/或预防糖尿病的药物靶点的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014151A2 (en) * 2001-08-10 2003-02-20 Genset S.A. Human secreted proteins, their encoding polynucleotides, and uses thereof
US20030073657A1 (en) * 2001-04-30 2003-04-17 Jorn-Peter Halle Use of alpha 1-antichymotrypsin polypeptides, or nucleic acids encoding them, or of a cell which is expressing an ACT polypeptide, or a nucleic acid encoding it, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing wounds and for identifying pharmacologically active substances
JP2003235573A (ja) * 2002-02-13 2003-08-26 Sumitomo Pharmaceut Co Ltd 糖尿病性腎症マーカーおよびその利用
WO2004084797A2 (ja) * 2003-02-28 2004-10-07 Hubit Genomix Inc 2型糖尿病関連遺伝子、およびその利用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088180A2 (en) * 2001-04-30 2002-11-07 Switch Biotech Ag Use of alpha 1-antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds
US9062306B2 (en) * 2003-04-29 2015-06-23 Biocrine Ab Methods for identifying compounds for treating type 1 diabetes
WO2005094200A2 (en) * 2003-06-20 2005-10-13 University Of Florida Biomarkers for differentiating between type 2 and type 2 diabetes
JP2005337952A (ja) * 2004-05-28 2005-12-08 Kanazawa Univ Tlo Inc 生活習慣病予知因子
EP1615035B1 (de) * 2004-07-07 2007-06-06 F.Hoffmann-La Roche Ag Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030073657A1 (en) * 2001-04-30 2003-04-17 Jorn-Peter Halle Use of alpha 1-antichymotrypsin polypeptides, or nucleic acids encoding them, or of a cell which is expressing an ACT polypeptide, or a nucleic acid encoding it, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing wounds and for identifying pharmacologically active substances
WO2003014151A2 (en) * 2001-08-10 2003-02-20 Genset S.A. Human secreted proteins, their encoding polynucleotides, and uses thereof
JP2003235573A (ja) * 2002-02-13 2003-08-26 Sumitomo Pharmaceut Co Ltd 糖尿病性腎症マーカーおよびその利用
WO2004084797A2 (ja) * 2003-02-28 2004-10-07 Hubit Genomix Inc 2型糖尿病関連遺伝子、およびその利用

Also Published As

Publication number Publication date
CA2661332A1 (en) 2008-03-13
WO2008030273A3 (en) 2008-08-28
AU2007293465A1 (en) 2008-03-13
CN101563597A (zh) 2009-10-21
WO2008030273A2 (en) 2008-03-13
EP2069768A2 (de) 2009-06-17
JP2010502946A (ja) 2010-01-28

Similar Documents

Publication Publication Date Title
EP2069768A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von typ-2-diabetes
EP2201370A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von typ-2-diabetes
EP2369017B8 (de) Verfahren und Zusammensetzungen auf Mikro-RNA-Basis zur Diagnose und Behandlung von Krankheiten im Zusammenhang mit dem Dickdarm
EP1924293A4 (de) Zusammensetzung und verfahren zur prävention und behandlung von diabetes typ i
EP1969147A4 (de) Mikro-rna-rna-basierte verfahren und zusammensetzungen zur diagnose und behandlung fester tumore
EP2007385A4 (de) Kardiovaskuläre zusammensetzung und ihre verwendung zur behandlung von morbus alzheimer
EP2212440A4 (de) Verfahren und zusammensetzungen zur diagnose und behandlung von adenokarzinomen der speiseröhre
SI2182981T1 (sl) Postopki in sestavki za zdravljenje in diagnozo fibroze
EP1991218A4 (de) Verwendung von cyclolignanen zur behandlung von diabetes typ 2 und als kontrazeptiva
ZA201003028B (en) Methods and compositions for diagnosis and treatment of amyloidosis
EP2070540A4 (de) Arzneizusammensetzung zur behandlung von diabetes typ 2 und chronischer neopathie
AU2007243282A8 (en) Compositions and methods for the treatment of cardiovascular disease
GB0608647D0 (en) Methods of diagnosis and treatment
EP2051732A4 (de) Diagnose- und behandlungsverfahren für stoffwechselstörungen
ZA200806808B (en) Treatment of stressed patients
GB0909297D0 (en) Composition for the treatment of skin conditions
EP1954800A4 (de) Zusammensetzung und verwendung von phyto-percolat zur behandlung von einer krankheit
ZA200808363B (en) Compounds and methods for diagnosis and treatment of leishmaniasis
EP1928247A4 (de) Zusammensetzung und verwendung von phytopercolat zur behandlung von krankheiten
EP1909809A4 (de) Verfahren und zusammensetzung zur behandlung von diabetes und seiner komplikationen
EP2010215A4 (de) Verfahren und zusammensetzungen zur behandlung von morbus crohn
GB0601950D0 (en) Compositions and methods of treating diabetes
EP2061486A4 (de) Verfahren und zusammensetzungen zum verschliessen und anheften von biologischem gewebe und medizinische anwendungen
EP1843781A4 (de) Zusammensetzung zur prävention, behandlung und diagnose von chronischen entzündlichen atemwegserkrankungen
EP1781826A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von orthopoxviren

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090331

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LIU, LIPING

Inventor name: GELBER, COHAVA

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20091222

17Q First examination report despatched

Effective date: 20100406

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120225